Diffusion Pharmaceuticals, based in Charlottesville, VA, is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases such as Dementia with Lewy Bodies, Alzheimer's Disease, and Stroke Recovery. Their approach involves targeting synaptic dysfunction early in the disease process to potentially reverse symptoms and disease progression.
With a pipeline including the development of Neflamapimod, an oral inhibitor of the protein kinase p38 alpha, Diffusion Pharmaceuticals aims to address the underlying causes of neurodegenerative disorders. Through ongoing clinical trials and research, the company is dedicated to providing hope through science for millions of individuals worldwide affected by these debilitating conditions.
Generated from the website